Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY)

Market Cap	11.52B -7.0%
Revenue (ttm)	3.00B +12.6%
Net Income	474.47M -4.4%
EPS	2.27 -4.4%
Shares Out	n/a
PE Ratio	24.29
Forward PE	14.44
Dividend	0.20 (1.47%)
Ex-Dividend Date	Nov 25, 2025

Volume	n/a
Average Volume	579
Open	13.64
Previous Close	13.64
Day's Range	13.64 - 13.64
52-Week Range	12.40 - 16.42
Beta	0.61
RSI	38.50
Earnings Date	Feb 17, 2026

About RICFY

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing’s syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1926
• Employees: 4,583
• Stock Exchange: OTCMKTS
• Ticker Symbol: RICFY

Financial Performance

In 2024, RICFY's revenue was 2.34 billion, an increase of 12.45% compared to the previous year's 2.08 billion. Earnings were 416.51 million, an increase of 7.01%.

Financial numbers in EUR